A Single Arm, Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma

Trial Profile

A Single Arm, Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 1 Jul 2023 to 1 Dec 2019.
    • 15 Nov 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2018.
    • 07 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top